AQX-1125
Phase 2- Indications
- Chronic obstructive pulmonary disease (COPD), Bladder pain syndrome/interstitial cystitis (BPS/IC), Atopic dermatitis (AD)
Company intelligence / Profile preview
Aquinox Pharmaceuticals
Vancouver, British Columbia, Canadasec.gov ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
AQX-1125 showed positive trends in primary endpoint and statistically significant changes on multiple secondary endpoints in Phase 2 LEADERSHIP trial for BPS/IC. However, the Phase 2 KINSHIP trial for atopic dermatitis failed to demonstrate efficacy.
- Therapeutic areas
- OncologyNephrologyImmunologyDermatologyHematology
- Modalities
- Small moleculesDe novo protein therapeutics
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Aquinox Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aquinox Pharmaceuticals.